Health ❯ Healthcare ❯ Clinical Trials

Phase 3 Trials

Efficacy Studies Eli Lilly Trials Drug Efficacy C-POST Trial Eli Lilly Efficacy and Safety Lecanemab BREAKWATER Trial EPCORE FL-1 Trial DESTINY-Breast09 Trial

FDA Approves Revtorpyk for HER2‑Low Breast Cancer but Launch and Safety Questions Loom

Supply readiness plus high rates of severe mouth inflammation create uncertainty over patient use and commercial uptake.

FDA Grants Accelerated Approval to Trutakna for IgA Nephropathy

FDA Approves Lumvoa for Thyroid Eye Disease

FDA Approves Utebzi as First Oral Carbapenem for Complicated UTIs

FDA Expands Capvaxive Use to At‑Risk Children and Teens

FDA Expands Hympavzi Approval to Patients Aged 6 and Older With Hemophilia

Roche Stops Phase 3 for Acmopatide After Positive Phase 2 in Type 1 Diabetes

FDA Approves Xocova as First Oral Post-Exposure COVID-19 Prophylaxis

EU Panel Recommends Braftovi Plus Cetuximab and FOLFOX for First‑Line BRAF‑Mutant Colorectal Cancer

Lilly’s Triple‑Agonist Retatrutide Produces Surgery‑Level Weight Loss in Phase 3 Trial

EMA Recommends Etcamah for ESR1‑Mutant Advanced Breast Cancer

FDA Approves Baxfendy, First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension

Moderna’s mRNA Flu Shot Tops Standard Vaccine in Large Phase 3 Trial

FDA Panel Rejects AstraZeneca Breast Cancer Drug, Backs Prostate Therapy

FDA Clears Vepdegestrant, First PROTAC Cancer Drug, for ESR1‑Mutated Breast Cancer

Boehringer’s Dual-Agonist Survodutide Cuts Body Weight by Up to 16.6% in Phase III Trial

FDA Clears Once-Weekly Saphnelo Pen for Self-Injection in Lupus

EMA Panel Recommends Redemplo for Familial Chylomicronaemia Syndrome

EMA Validates Astellas Bid to Add Padcev–Keytruda Combo for Perioperative Muscle-Invasive Bladder Cancer

Xenon Presents Phase 3 Azetukalner Results and 48‑Month Data at American Academy of Neurology Meeting